Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Piramal PharmaNSE:PPLPHARMA +3.32%49 PS Ratio is 2.71 as of Jul. 22, 2026, which is 12% above its 10-year median of 2.42. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 49/100 and a GF Value™ of ₹175.72 (Fairly Valued). The stock has 5 warning signs investors should review. Among 952 Drug Manufacturers companies, Piramal Pharma ranks worse than 55.67% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Piramal Pharma's share price is ₹184.81.
Piramal Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹68.15. Hence, Piramal Pharma's PS Ratio for today is 2.71.
Warning Sign:
Piramal Pharma Ltd stock PS Ratio (=2.73) is close to 1-year high of 2.96.
The historical rank and industry rank for Piramal Pharma's PS Ratio or its related term are showing as below:
NSE:PPLPHARMA'
s PS Ratio Range Over the Past 10 Years
Min: 1.15 Med: 2.42 Max: 4.29
Current: 2.71
During the past 6 years, Piramal Pharma's highest PS Ratio was 4.29. The lowest was 1.15. And the median was 2.42.
NSE:PPLPHARMA's PS Ratio is ranked worse than 55.67% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs NSE:PPLPHARMA: 2.71
Piramal Pharma Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Piramal Pharma was -3.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.30% per year.
During the past 6 years, Piramal Pharma's highest 3-Year average Revenue per Share Growth Rate was 8.60% per year. The lowest was 4.30% per year. And the median was 6.45% per year.
Back to Basics: PS Ratio
Piramal Pharma (NSE:PPLPHARMA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Piramal Pharma PS Ratio Related Terms
Piramal Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Piramal Pharma's Share Price of today is ₹184.81. Piramal Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹68.15.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Piramal Pharma (NSE:PPLPHARMA) has a PS Ratio of 2.71 as of Jul. 22, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Piramal Pharma and its competitors. This is 12% above median its historical median of 2.42. Over the past decade, Piramal Pharma's PS Ratio has ranged from 1.15 to 4.29. According to the industry distribution chart, Piramal Pharma ranks #530 out of 952 companies in the Drug Manufacturers industry, placing it in the top 55.7%.
Is Piramal Pharma's PS Ratio too high?
Piramal Pharma's current PS Ratio of 2.71 is 12% above median its 10-year median of 2.42. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 4.29. The Drug Manufacturers industry median PS Ratio is 2.29. Piramal Pharma's value of 2.71 is 18.3% above this industry median. Based on the distribution chart, Piramal Pharma ranks #530 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Piramal Pharma has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #530 out of 952 companies for PS Ratio. This places Piramal Pharma in the lower half of its industry. The industry median PS Ratio is 2.29. Piramal Pharma's value of 2.71 is 18.3% above this benchmark. Historically, Piramal Pharma's own PS Ratio has ranged from 1.15 to 4.29 over the past decade. While the company's 10-year median is 2.42 vs. the industry median of 2.29, Piramal Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.29, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current PS Ratio of 2.71 is 18.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current PS Ratio is 2.71, which is 12% above median its own 10-year median of 2.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹175.72, compared to a current price of ₹184.81 — trading 5.2% above its estimated fair value. The current PS Ratio is 2.71, which is 12% above median its 10-year median of 2.42 and 18.3% above the Drug Manufacturers industry median of 2.29. Piramal Pharma's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current PS Ratio is 2.71 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued.
The current stock price of ₹184.81 is trading 5.2% above its estimated GF Value™ of ₹175.72.
GuruFocus considers Piramal Pharma to be Fairly Valued.
Key valuation signals for NSE:PPLPHARMA:
PS Ratio: 2.71 (12% above median its 10-year median of 2.42)
GF Value™: ₹175.72 vs. price of ₹184.81 (5.2% above fair value)
Industry Position: 18.3% above the Drug Manufacturers median (#530 of 952)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
49GF Score
Get the complete analysis for NSE:PPLPHARMA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
